Impact of demographic and clinical factors on elagolix plus add-back therapy effects on patient-reported nonbleeding symptoms in women with heavy menstrual bleeding and uterine fibroids: a post hoc analysis of data from two clinical trials
James A. Simon(George Washington University), Michael C. Snabes(AbbVie (United States)), Susan Jewell(Medisch Centrum Alkmaar), Elizabeth A. Stewart(Beijing Obstetrics and Gynecology Hospital), Moming Li(AbbVie (United States))
Cited by 1
Related Papers
MR Imaging–guided Focused Ultrasound Surgery of Uterine Leiomyomas: A Feasibility Study
|Radiology|2003|589
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist
|New England Journal of Medicine|2017|492
Fluorescence In Situ Hybridization (FISH) as an Ancillary Diagnostic Tool in the Diagnosis of Melanoma
|The American Journal of Surgical Pathology|2009|470
A Highly Specific and Discriminatory FISH Assay for Distinguishing Between Benign and Malignant Melanocytic Neoplasms
|The American Journal of Surgical Pathology|2012|227
Long-Term Outcomes of Elagolix in Women With Endometriosis
|Obstetrics and Gynecology|2018|132